Literature DB >> 22495362

Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma.

Oluwole Fadare1, Sharon X Liang.   

Abstract

Hepatocyte nuclear factor 1-beta (HNF1β) has recently emerged as a relatively sensitive and specific marker for ovarian clear cell carcinoma. The purpose of this study is to assess the diagnostic utility of this marker for endometrial clear cell carcinoma. Immunohistochemical analysis was performed on 75 endometrial tissues using a goat polyclonal antibody raised against a peptide mapping at the C-terminus of human HNF1β protein. The 75 cases included 15 clear cell carcinomas, 20 endometrioid carcinomas, 15 endometrial serous carcinomas/uterine papillary serous carcinomas, 20 cases of normal endometrium, 2 cases of clear cell metaplasia, and 3 cases of Arias Stella reaction. Staining interpretations were based on a semiquantitative scoring system, a 0 to 12+ continuous numerical scale that was derived by multiplying the extent of staining (0 to 4+ scale) by the intensity of staining (0 to 3+ scale) for each case. HNF1β expression was found to be present in a wide spectrum of tissues. Twenty-seven (54%) of the 50 carcinomas displayed at least focal nuclear HNF1β expression, including 11 (73%) of 15, 9 (60%) of 15, and 7 (35%) of 20 clear cell, serous, and endometrioid carcinomas, respectively. The average nuclear staining scores for clear cell carcinomas, endometrioid carcinomas, and serous carcinomas were 5.2, 1.4, and 4.1, respectively. Clear cell carcinomas and endometrioid carcinomas displayed statistically significant differences regarding their nuclear staining scores (P = 0.0027), but clear cell carcinomas and endometrial serous carcinomas did not (P = 0.45). The calculated sensitivity of any nuclear HNF1β expression in classifying a carcinoma as being of the clear cell histotype was 73%, whereas the specificity was 54%. Nineteen of 20 normal endometrium samples displayed at least focal nuclear expression of HNF1β, and this expression was often diffuse. The 5 cases of benign histologic mimics of clear cell carcinomas (Arias Stella reaction and clear cell metaplasia) displayed some degree of HNF1β immunoreactivity, with an average nuclear staining score of 7.3. We conclude that although HNF1β is frequently expressed in clear cell carcinomas, it should be used with caution as a diagnostic marker because of its lack of specificity. It neither distinguishes endometrial serous carcinomas from clear cell carcinomas nor clear cell carcinomas from its benign mimics. The greatest diagnostic utility of HNF1β expression may be in a supportive evidentiary role favoring clear cell carcinoma when the principal differential diagnostic consideration is endometrioid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495362     DOI: 10.1097/PAI.0b013e31824973d1

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  16 in total

1.  Utility of α-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.

Authors:  Oluwole Fadare; Vinita Parkash; Katja Gwin; Krisztina Z Hanley; Elke A Jarboe; Sharon X Liang; Charles M Quick; Wenxin Zheng; Kojo R Rawish; Jonathan L Hecht; Mohamed M Desouki
Journal:  Hum Pathol       Date:  2013-10-10       Impact factor: 3.466

Review 2.  Clear cell carcinoma of ovary and uterus.

Authors:  Rosalind M Glasspool; Iain A McNeish
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 3.  Practical issues in the diagnosis of serous carcinoma of the endometrium.

Authors:  Sonia Gatius; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

4.  HNF-1β in ovarian carcinomas with serous and clear cell change.

Authors:  Deborah DeLair; Guangming Han; Julie A Irving; Samuel Leung; Carol A Ewanowich; Teri A Longacre; Cyril B Gilks; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2013-11       Impact factor: 2.762

5.  Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions.

Authors:  Kristýna Němejcová; Ivana Tichá; Petra Kleiblová; Michaela Bártů; David Cibula; Kateřina Jirsová; Pavel Dundr
Journal:  Pathol Oncol Res       Date:  2015-12-19       Impact factor: 3.201

6.  Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.

Authors:  Martin Köbel; Bo Meng; Lien N Hoang; Noorah Almadani; Xiaodong Li; Robert A Soslow; C Blake Gilks; Cheng-Han Lee
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

7.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

8.  Napsin A is a specific marker for ovarian clear cell adenocarcinoma.

Authors:  Yoriko Yamashita; Tetsuro Nagasaka; Aya Naiki-Ito; Shinya Sato; Shugo Suzuki; Shinya Toyokuni; Masafumi Ito; Satoru Takahashi
Journal:  Mod Pathol       Date:  2014-04-11       Impact factor: 7.842

9.  Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment.

Authors:  Oluwole Fadare; Idris L Renshaw; Sharon X Liang
Journal:  J Cancer       Date:  2012-03-10       Impact factor: 4.207

10.  Napsin-A and AMACR are Superior to HNF-1β in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract.

Authors:  Jennifer Pors; Sheila Segura; Angela Cheng; Jennifer X Ji; Basile Tessier-Cloutier; Dawn Cochrane; Daniel J Fix; Kay Park; Blake Gilks; Lynn Hoang
Journal:  Appl Immunohistochem Mol Morphol       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.